Immune checkpoint blockade therapy uses immune checkpoint blocking agents to relieve the inhibitory pressure on CD8+ T cells and restore their sensitivity and killing ability to tumor cells (Darvin et al., 2018). The gene discussed is CD8A; the disease is neoplasm.